Page last updated: 2024-09-05

sorafenib and Dermatitis Medicamentosa

sorafenib has been researched along with Dermatitis Medicamentosa in 84 studies

Research

Studies (84)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	29 (34.52)	29.6817
2010's	55 (65.48)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chang, YY; Ensslin, CJ; Hsieh, CH; Hsieh, SY; Kao, PH; Kuo, TT; Miller, LS; Wu, MY; Yang, CH	1
Borgia, F; Cannavò, SP; Franzè, MS; Lentini, M; Saitta, C; Vaccaro, M	1
Kira, Y; Mizukami, Y; Sugawara, K; Tsuruta, D	1
Arnold, AW; Kiritsi, D	1
Chen, L; Cheng, Y; Feng, L; Fu, S; Guan, F; Jiang, Z; Lam, W; Lu, H; Tian, A; Zhang, J	1
Hirai, S; Kakinoki, N; Kamoshida, T; Ochi, M; Ohkawara, A; Ohkawara, H; Yanaka, A	1
Aggarwal, D; Daroach, M; Guliani, A; Kumaran, MS; Radotra, BD	1
Bandyopadhyay, D; Bose, P; Deng, X; Dent, P; Gordon, SW; Kmieciak, M; Lee, HM; Matherly, SC; McGuire, WP; Nguyen, T; Poklepovic, AS; Roberts, JD; Ryan, AA; Shafer, DA; Shrader, EE; Sterling, RK; Tombes, MB	1
Berbis, P; Buono, JP; Chambelland, A; Delaporte, E; Desmedt, E; Fongue, J; Koeppel, MC	1
Goldschmidt, H; Gütgemann, I; Hose, D; Moehler, T; Neben, K; Raab, MS; Schmidt-Wolf, IG; Witzens-Harig, M; Yordanova, A	1
Fujiyama, Y; Hira, D; Morita, SY; Noda, S; Shioya, M; Terada, T	1
Degen, A; Egberts, F; Garbe, C; Gutzmer, R; Hauschild, A; Kilian, K; Poppe, LM; Trefzer, U; Ugurel, S; Weichenthal, M	1
Aronson, P; Uhlenhake, EE; Watson, AC	1
Derbel Miled, O; Dionne, C; Droz, JP; Flechon, A; Negrier, S; Neidhart, EM; Segura-Ferlay, C; Terret, C	1
Carriere, C; Eisendle, K; Kluge, R; Mazzoleni, G; Pichler, M	1
Eberst, E; Guillot, B; Kluger, N; Pageaux, GP; Rigau, V	1
Abdel-Rahman, O; Fouad, M	1
Ara, M; Pastushenko, E	1
Bella, A; Guerra, JR; Lolo, D; Suelves, AM	1
Akarsu, S; Çarsanbali, S; Fetil, E; İlknur, T; Lebe, B	1
Batalla, A; Blay, P; Curto, JR; Menéndez, L	1
Ando, Y; Bonichon, F; Brose, MS; Chung, J; Fassnacht, M; Fugazzola, L; Gao, M; Hadjieva, T; Hasegawa, Y; Kappeler, C; Meinhardt, G; Park, DJ; Schlumberger, M; Shi, Y; Shong, YK; Smit, JW; Worden, F	1
Cardones, AR; Chu, EY; Dahut, WL; Kong, HH; Pichard, DC	1
Amitay-Laish, I; Didkovsky, E; Hendler, D; Hodak, E; Lotem, M; Merims, S; Ollech, A; Popovtzer, A; Stemmer, SM	1
Chen, X; Cui, T; Diao, X; Huang, S; Sun, J	1
Alfieri, S; Bergamini, C; Bossi, P; Civelli, E; Cortelazzi, B; Dagrada, GP; Granata, R; Imbimbo, M; Licitra, L; Lo Vullo, S; Locati, LD; Mariani, L; Mirabile, A; Morosi, C; Orlandi, E; Perrone, F; Pilotti, S; Quattrone, P; Resteghini, C; Saibene, G	1
Chanco Turner, ML; Chevreau, C; Fojo, T; Hornyak, TJ; Kong, HH; Sibaud, V	1
Autier, J; Escudier, B; Robert, C; Spatz, A; Wechsler, J	1
Cicek, D; Dagli, FA; Haligur, BD; Kandi, B; Karaoglu, A	1
Borrás-Blasco, J; Casterá, ME; Galán Brotons, A; Rosique-Robles, JD; Vicent Verge, JM	1
Kung, EF; Maddox, JS; Petronic-Rosic, V; Sethi, A	1
Schneeberger, A; Tatzreiter, G; Udvardi, A; Volc-Platzer, B; Wolber, C	1
Bukowski, RM	1
Dubauskas, Z; Hwu, P; Jonasch, E; Kunishige, J; Prieto, VG; Tannir, NM	1
Desmedt, E; Digue, L; Milano, G; Mortier, L; Ravaud, A	1
Feito Rodríguez, M; Feltes, RA; González-Beato, MJ	1
Burkemper, NM; Chappell, JA; Semchyshyn, N	1
Chang, SE; Choi, JH; Kang, YK; Koh, JK; Lee, JL; Lee, MW; Lee, WJ; Moon, KC	1
Kong, HH; Turner, ML	1
Carbonell, CE; Coleman, TA; Davis, CH; Davis, WB; La Vine, DB	1
Botella-Estrada, R; Echeverría, B; Guillén, C; Llombart, B	1
Lipworth, AD; Robert, C; Zhu, AX	1
Cabrera, R; Nelson, DR	1
Aitini, E; Bengala, C; Bertolini, F; Boni, C; Conte, P; Dealis, C; Del Giovane, C; Depenni, R; Fontana, A; Luppi, G; Malavasi, N; Zironi, S	1
Wood, LS	1
Chernick, MS; Figg, WD; Gardner, ER; Jain, L; Kong, HH	1
Addeo, R; Caraglia, M; Colucci, G; Del Prete, S; Frezza, AM; Giuliani, F; Montella, L; Rizzo, S; Russo, A; Santini, D; Tonini, G; Venditti, O; Vincenzi, B	1
Chon, SY; Diamantis, ML	1
Chen, PJ; Cheng, AL; Ding, YH; Hsu, C; Hsu, CH; Lin, ZZ; Shao, YY; Shen, YC	1
Alter, M; Degen, A; Gutzmer, R; Kapp, A; Satzger, I; Schenck, F; Völker, B	1
Ahn, CS; Hwang, S; Kang, YK; Kim, KH; Kim, TW; Lee, HC; Lee, SG; Moon, DB; Ryoo, BY; Ryu, MH; Suh, DJ; Yoon, DH	1
Amoh, Y; Eto, H; Iwamura, M; Katsuoka, K; Mii, S; Tanabe, K	1
Eames, T; Staehler, M; Wollenberg, A	1
Dann, F; Kelly, K; Laquer, V; Saedi, N	1
Armstrong, C; Hull, D	1
Bustamante, J; Castells, L; de La Mata, M; Delgado, M; Forner, A; Matilla, A; Moreno, JM; Reig, M; Varela, M	1
Avril, MF; Barete, S; Billemont, B; Blanchet, B; Carlotti, A; Francès, C; Franck, N; Goldwasser, F; Moguelet, P; Ropert, S	1
Bednaríková, D; Kocák, I	1
Donaldson, MR; Smith, JL; Stetson, CL	1
Chen, YJ; Liang, CP; Shen, JL; Yang, CS	1
Betlloch, I; Cuesta, L; Latorre, N; Monteagudo, A; Toledo, F	1
Boers-Doets, C; Chrysou, M; Edmonds, K; Hull, D; Koldenhof, J; Molassiotis, A; Spencer-Shaw, A	1
Paz, C; Querfeld, C; Shea, CR	1
Budak, K; Pestalozzi, B; Weisshaupt, Ch	1
Borbujo, JM; Córdoba, S; Espinosa, P; Martínez-Morán, C; Meseguer-Yebra, C; Nájera, L; Romero-Maté, A; Ruiz-Casado, AI	1
Chevreau, C; Cottura, E; Garrido-Stowhas, I; Sibaud, V	1
Hughes, M; Pickert, A; Wells, M	1
Farley-Loftus, R; Lewin, J; Pomeranz, MK	1
Eisen, T; Escudier, B; Izzedine, H; Mulders, P; Pyle, L; Robert, C; Sternberg, CN; Zbinden, S	1
He, X; Hu, BS; Li, Y; Lu, LG; Luo, XN; Shao, PJ; Yu, XY	1
Chapman, R; Dowlati, A; Fu, P; Lavertu, P; Nagaiah, G; Remick, SC; Savvides, P; Wasman, J; Wright, JJ	1
Awada, A; Brueckner, A; Christensen, O; Clark, JW; Hirte, H; Hofstra, E; Piccart, P; Schwartz, B; Seeber, S; Strumberg, D; Voliotis, D	1
Desai, A; Lacouture, ME; Laumann, AE; Petronic-Rosic, V; Ratain, MJ; Soltani, K; Stadler, WM	1
Haseke, N; Heinemann, G; Schöppler, G; Stadler, T; Staehler, M; Stief, CG	1
Kuzel, T; Lacouture, ME; Lai, SE	1
Robert, C	1
Akaza, H; Murai, M; Naito, S; Nakajima, K; Tsukamoto, T	1
Manchen, B; Wood, LS	1
Beldner, M; Burges, GE; Chaudhary, UB; Dewaay, D; Jacobson, M; Maize, JC	1
Chang, JW; Chang, YC; Chuang, CK; Hsieh, JJ; Kuo, TT; Lin, WC; Lin, YC; Pang, ST; Yang, CH	1
Chu, D; Fillos, T; Lacouture, ME; Wu, S	1
Autier, J; Mateus, C; Robert, C; Spatz, A; Wechsler, J	1
Chevreau, C; Delord, JP; Deslandres, M; Sibaud, V	1
Burgin, S; Heidary, N; Naik, H	1

Reviews

20 review(s) available for sorafenib and Dermatitis Medicamentosa

Article	Year
Psoriasiform drug eruption secondary to sorafenib: case series and review of the literature. Cutis, 2019, Volume: 104, Issue:3 Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Eruptions; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Psoriasis; Sorafenib	2019
Risk of mucocutaneous toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis. Expert review of anticancer therapy, 2014, Volume: 14, Issue:6 Topics: Alopecia; Antineoplastic Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Eruptions; Hand-Foot Syndrome; Humans; Incidence; Mucositis; Neoplasm Proteins; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pruritus; Randomized Controlled Trials as Topic; Receptor Protein-Tyrosine Kinases; Risk; Sorafenib	2014
Antiangiogenic agents and the skin: cutaneous adverse effects of sorafenib, sunitinib, and bevacizumab. Actas dermo-sifiliograficas, 2014, Volume: 105, Issue:10 Topics: Administration, Cutaneous; Angiogenesis Inhibitors; Antineoplastic Agents; Bevacizumab; Drug Eruptions; Drug-Related Side Effects and Adverse Reactions; Humans; Indoles; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib	2014
Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology, 2009, Volume: 77, Issue:5 Topics: Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Erythema; Foot Dermatoses; Hand Dermatoses; Humans; Indoles; Niacinamide; Paresthesia; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Risk Factors; Sorafenib; Sunitinib; Syndrome	2009
Review article: the management of hepatocellular carcinoma. Alimentary pharmacology & therapeutics, 2010, Feb-15, Volume: 31, Issue:4 Topics: Ablation Techniques; Adult; Antineoplastic Agents; Asian People; Benzenesulfonates; Biopsy; Black People; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Contrast Media; Drug Eruptions; Female; Health Care Costs; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Incidence; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Population Surveillance; Practice Guidelines as Topic; Pyridines; Quality of Life; Randomized Controlled Trials as Topic; Recurrence; Risk Factors; Sorafenib; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome; United States; Young Adult	2010
Management of vascular endothelial growth factor and multikinase inhibitor side effects. Clinical journal of oncology nursing, 2009, Volume: 13 Suppl Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Diarrhea; Drug Eruptions; Drug Monitoring; Fatigue; Humans; Indoles; Interleukin-2; Intracellular Signaling Peptides and Proteins; Kidney Neoplasms; Male; Niacinamide; Oncology Nursing; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2009
The hand-foot-syndrome associated with medical tumor therapy - classification and management. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2010, Volume: 8, Issue:9 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Dermatologic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; Foot Dermatoses; Hand Dermatoses; Humans; Keratoderma, Palmoplantar; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib	2010
[Cutaneous side effects of the multikinase inhibitors sorafenib and sunitinib]. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2010, Volume: 61, Issue:8 Topics: Antineoplastic Agents; Benzenesulfonates; Drug Delivery Systems; Drug Eruptions; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Structure-Activity Relationship; Sunitinib	2010
[Hand-foot syndrome after administration of tyrosinkinase inhibitors]. Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, 2010, Volume: 23, Issue:5 Topics: Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Foot Dermatoses; Hand Dermatoses; Humans; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Syndrome	2010
Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group. European journal of oncology nursing : the official journal of European Oncology Nursing Society, 2012, Volume: 16, Issue:2 Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Diarrhea; Drug Eruptions; Europe; Fatigue; Foot Dermatoses; Hand Dermatoses; Humans; Kidney Neoplasms; Liver Neoplasms; Molecular Targeted Therapy; Mucositis; Niacinamide; Nursing Assessment; Phenylurea Compounds; Practice Guidelines as Topic; Pyridines; Randomized Controlled Trials as Topic; Societies, Nursing; Sorafenib	2012
[Dermatologic side effects induced by new angiogenesis inhibitors]. Bulletin du cancer, 2011, Volume: 98, Issue:10 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Drug Eruptions; Humans; Indazoles; Indoles; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Skin; Sorafenib; Sulfonamides; Sunitinib	2011
Targeted therapies for renal cell carcinoma: review of adverse event management strategies. Journal of the National Cancer Institute, 2012, Jan-18, Volume: 104, Issue:2 Topics: Anorexia; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cardiovascular System; Drug Eruptions; Europe; Everolimus; Evidence-Based Medicine; Gastrointestinal Tract; Humans; Hypothyroidism; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pneumonia; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Weight Loss; Wound Healing	2012
Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome? European journal of cancer (Oxford, England : 1990), 2006, Volume: 42, Issue:4 Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Clinical Trials, Phase I as Topic; Dose-Response Relationship, Drug; Drug Eruptions; Exanthema; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome	2006
[Managing the side effects of angiogenetic inhibitors in metastatic renal cell carcinoma]. Der Urologe. Ausg. A, 2006, Volume: 45, Issue:10 Topics: Adult; Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Drug Eruptions; Female; Gastrointestinal Diseases; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome	2006
[Cutaneous side effects of antiangiogenic agents]. Bulletin du cancer, 2007, Volume: 94 Spec No Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Drug Eruptions; Humans; Indoles; Niacinamide; Phenylurea Compounds; Pigmentation Disorders; Pyridines; Pyrroles; Skin Diseases; Sorafenib; Sunitinib	2007
Sorafenib: a promising new targeted therapy for renal cell carcinoma. Clinical journal of oncology nursing, 2007, Volume: 11, Issue:5 Topics: Administration, Oral; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Diarrhea; Drug Delivery Systems; Drug Eruptions; Drug Interactions; Drug Monitoring; Fatigue; Humans; Hypertension; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Nurse's Role; Nursing Assessment; Oncology Nursing; Patient Compliance; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Risk Factors; Social Support; Sorafenib; Survival Rate; Treatment Outcome	2007
Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. Acta oncologica (Stockholm, Sweden), 2008, Volume: 47, Issue:2 Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Drug Eruptions; Foot; Hand; Humans; Incidence; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Risk Assessment; Risk Factors; Skin; Skin Diseases; Sorafenib	2008
[Cutaneous side effects of sorafenib and sunitinib]. Annales de dermatologie et de venereologie, 2008, Volume: 135, Issue:2 Topics: Acrodermatitis; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Hair Diseases; Humans; Indoles; Nail Diseases; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Skin; Sorafenib; Sunitinib	2008
[Cutaneous side effects associated with epidermal growth factor receptor and tyrosine kinase inhibitors]. Annales de dermatologie et de venereologie, 2008, Volume: Spec No 1 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Benzenesulfonates; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib	2008
Chemotherapeutic agents and the skin: An update. Journal of the American Academy of Dermatology, 2008, Volume: 58, Issue:4 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites; Antineoplastic Agents; Benzamides; Benzenesulfonates; Cetuximab; Drug Eruptions; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gefitinib; Hair Diseases; Humans; Imatinib Mesylate; Indoles; Mucous Membrane; Nail Diseases; Niacinamide; Phenylurea Compounds; Piperazines; Platinum Compounds; Proteasome Inhibitors; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Skin; Skin Diseases; Sorafenib; Sunitinib; Taxoids	2008

Trials

10 trial(s) available for sorafenib and Dermatitis Medicamentosa

Article	Year
Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma. American journal of clinical oncology, 2019, Volume: 42, Issue:8 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemical and Drug Induced Liver Injury; Drug Eruptions; Female; Humans; Hypokalemia; Hypophosphatemia; Liver Neoplasms; Male; Middle Aged; Sorafenib; Thrombocytopenia; Vorinostat	2019
Sorafenib in patients with refractory or recurrent multiple myeloma. Hematological oncology, 2013, Volume: 31, Issue:4 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Eruptions; Drug Resistance, Neoplasm; Fatigue; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Interferon-alpha; Lenalidomide; Male; Middle Aged; Molecular Targeted Therapy; Multiple Myeloma; Neoplasm Proteins; Niacinamide; Pain; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Recurrence; Remission Induction; Salvage Therapy; Sorafenib; Thalidomide; Treatment Outcome	2013
Cutaneous side effects of combined therapy with sorafenib and pegylated interferon alpha-2b in metastatic melanoma (phase II DeCOG trial). Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2013, Volume: 11, Issue:9 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Causality; Comorbidity; Drug Eruptions; Female; Germany; Humans; Interferon-alpha; Male; Melanoma; Middle Aged; Niacinamide; Phenylurea Compounds; Polyethylene Glycols; Prevalence; Recombinant Proteins; Risk Factors; Skin Neoplasms; Sorafenib; Treatment Outcome	2013
Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer. Endocrine-related cancer, 2015, Volume: 22, Issue:6 Topics: Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Aged; Antineoplastic Agents; Carcinoma, Papillary; Diarrhea; Disease-Free Survival; Drug Eruptions; Drug Resistance, Neoplasm; Dyspnea; Fatigue; Female; Humans; Hypertension; Hypocalcemia; Incidence; Iodine Radioisotopes; Male; Middle Aged; Neoplasms, Second Primary; Niacinamide; Phenylurea Compounds; Prevalence; Protein Kinase Inhibitors; Radiopharmaceuticals; Sorafenib; Thyroid Neoplasms; Weight Loss	2015
A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact. European journal of cancer (Oxford, England : 1990), 2016, Volume: 69 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Adenoid Cystic; Carcinoma, Mucoepidermoid; Diarrhea; Disease-Free Survival; Drug Eruptions; Fatigue; Hand-Foot Syndrome; Humans; Hypertension; Immunohistochemistry; Male; Middle Aged; Myoepithelioma; Neoplasm Metastasis; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Proto-Oncogene Proteins c-ret; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Salivary Gland Neoplasms; Sorafenib; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2; Young Adult	2016
Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Archives of dermatology, 2008, Volume: 144, Issue:7 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Double-Blind Method; Drug Eruptions; Female; Foot Dermatoses; France; Hand Dermatoses; Humans; Incidence; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Pyridines; Severity of Illness Index; Sorafenib	2008
Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. British journal of cancer, 2010, Jan-05, Volume: 102, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Bile Duct Neoplasms; Biliary Tract Neoplasms; Carcinoma; Cholangiocarcinoma; Disease-Free Survival; Drug Eruptions; Fatigue; Female; Gallbladder Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Salvage Therapy; Sorafenib	2010
Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. Journal of hepatology, 2010, Volume: 53, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Diarrhea; Disease-Free Survival; Drug Eruptions; Fatigue; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tegafur; Uracil	2010
Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid. Thyroid : official journal of the American Thyroid Association, 2013, Volume: 23, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma; Drug Eruptions; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Hypertension; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Sorafenib; Survival Analysis; Thyroid Carcinoma, Anaplastic; Thyroid Gland; Thyroid Neoplasms	2013
Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Japanese journal of clinical oncology, 2007, Volume: 37, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Eruptions; Female; Humans; Kidney Neoplasms; Lipase; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib	2007

Other Studies

54 other study(ies) available for sorafenib and Dermatitis Medicamentosa

Article	Year
Nodular-cystic eruption in course of sorafenib administration for hepatocarcinoma: An unconventional skin reaction requiring unconventional treatment. International journal of immunopathology and pharmacology, 2017, Volume: 30, Issue:3 Topics: Aminolevulinic Acid; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Eruptions; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Photochemotherapy; Photosensitizing Agents; Protein Kinase Inhibitors; Sorafenib	2017
Sorafenib stimulates human skin type mast cell degranulation and maturation. Journal of dermatological science, 2017, Volume: 88, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Apoptosis; Biopsy; Cell Count; Cell Degranulation; Cell Proliferation; Drug Eruptions; Extracellular Signal-Regulated MAP Kinases; Female; Flavonoids; Humans; Male; Mast Cells; Middle Aged; Niacinamide; Organ Culture Techniques; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Signal Transduction; Skin; Sorafenib; Stem Cell Factor; Vascular Endothelial Growth Factor A; Wortmannin; Young Adult	2017
Image Gallery: Sorafenib-induced acne of the buttocks. The British journal of dermatology, 2017, Volume: 177, Issue:6 Topics: Acneiform Eruptions; Aged; Antineoplastic Agents; Buttocks; Carcinoma, Hepatocellular; Drug Eruptions; Humans; Liver Neoplasms; Male; Protein Kinase Inhibitors; Sorafenib	2017
Multikinase inhibitor sorafenib induces skin toxicities in tumor-bearing mice. Cancer chemotherapy and pharmacology, 2018, Volume: 81, Issue:6 Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Drug Eruptions; Female; Humans; Liver Neoplasms; Mice; Mice, Nude; Protein Kinase Inhibitors; Signal Transduction; Skin; Smad Proteins; Sorafenib; Transforming Growth Factor beta1; Xenograft Model Antitumor Assays	2018
Multikinase inhibitor-associated hand-foot skin reaction as a predictor of outcomes in patients with hepatocellular carcinoma treated with sorafenib. World journal of gastroenterology, 2018, Jul-28, Volume: 24, Issue:28 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Eruptions; Female; Foot; Hand; Humans; Incidence; Liver Neoplasms; Male; Medication Adherence; Middle Aged; Niacinamide; Pharmacists; Phenylurea Compounds; Protein Kinase Inhibitors; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Skin; Sorafenib; Survival Analysis; Treatment Failure	2018
Severe hand-foot skin reaction and erythema multiforme-like lesions due to sorafenib. Postgraduate medical journal, 2018, Volume: 94, Issue:1115 Topics: Antineoplastic Agents; Biopsy; Drug Eruptions; Erythema Multiforme; Female; Foot; Hand; Humans; Middle Aged; Sorafenib	2018
[Nodulocystic eruption induced by sorafenib]. Annales de dermatologie et de venereologie, 2019, Volume: 146, Issue:10 Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Eruptions; Female; Humans; Liver Neoplasms; Male; Middle Aged; Sorafenib	2019
Pharmacokinetic interaction between sorafenib and prednisolone in a patient with hepatocellular carcinoma. Cancer chemotherapy and pharmacology, 2013, Volume: 72, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Carcinoma, Hepatocellular; Drug Eruptions; Drug Interactions; Drug Monitoring; Female; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Prednisolone; Sorafenib; Stomatitis; Treatment Outcome	2013
Sorafenib induced eruptive melanocytic lesions. Dermatology online journal, 2013, May-15, Volume: 19, Issue:5 Topics: Antineoplastic Agents; Brachytherapy; Carcinoma, Renal Cell; Drug Eruptions; Fatal Outcome; Humans; Kidney Neoplasms; Lentigo; Lung Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib	2013
Sorafenib and sunitinib for elderly patients with renal cell carcinoma. Journal of geriatric oncology, 2013, Volume: 4, Issue:3 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Asthenia; Carcinoma, Renal Cell; Disease-Free Survival; Drug Eruptions; Female; Humans; Indoles; Kidney Neoplasms; Male; Neutropenia; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome	2013
Acne inversa-like lesions associated with the multi-kinase inhibitor sorafenib. Clinical and experimental dermatology, 2014, Volume: 39, Issue:2 Topics: Aged; Antineoplastic Agents; Drug Eruptions; Hidradenitis Suppurativa; Humans; Leg Dermatoses; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib	2014
Perforating folliculitis-like reaction related to sorafenib. Cutis, 2014, Volume: 93, Issue:1 Topics: Antineoplastic Agents; Drug Eruptions; Folliculitis; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib	2014
Hand, foot and scrotal blisters in a patient with cancer receiving oral chemotherapy. BMJ case reports, 2014, May-19, Volume: 2014 Topics: Administration, Oral; Administration, Topical; Adrenal Cortex Hormones; Aged; Blister; Carcinoma, Hepatocellular; Drug Eruptions; Foot Dermatoses; Hand Dermatoses; Humans; Liver Neoplasms; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Scrotum; Severity of Illness Index; Sorafenib; Syndrome; Treatment Outcome	2014
Sorafenib-associated psoriasiform eruption in a patient with hepatocellular carcinoma. Journal of drugs in dermatology : JDD, 2014, Volume: 13, Issue:8 Topics: Administration, Oral; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Eruptions; Humans; Liver Neoplasms; Lung Neoplasms; Male; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Sorafenib	2014
Delayed onset perforating folliculitis associated with sorafenib. The Australasian journal of dermatology, 2014, Volume: 55, Issue:3 Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Drug Eruptions; Folliculitis; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Time Factors	2014
Sorafenib-Induced Eruption Mimicking Erythema Multiforme. JAMA dermatology, 2016, Volume: 152, Issue:2 Topics: Aged; Antineoplastic Agents; Drug Eruptions; Erythema Multiforme; Humans; Male; Niacinamide; Phenylurea Compounds; Sorafenib	2016
Widespread morbilliform rash due to sorafenib or vemurafenib treatment for advanced cancer; experience of a tertiary dermato-oncology clinic. International journal of dermatology, 2016, Volume: 55, Issue:4 Topics: Aged; Antineoplastic Agents; Drug Eruptions; Exanthema; Female; Humans; Indoles; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Steroids; Sulfonamides; Vemurafenib	2016
A case report: delayed high fever and maculopapules during Sorafenib treatment of ectopic hepatocellular carcinoma. BMC cancer, 2016, 07-27, Volume: 16 Topics: Carcinoma, Hepatocellular; Drug Eruptions; Fever; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prednisone; Sorafenib; Treatment Outcome	2016
Sorafenib-induced eruptive melanocytic lesions. Archives of dermatology, 2008, Volume: 144, Issue:6 Topics: Administration, Oral; Antineoplastic Agents; Benzenesulfonates; Biopsy; Carcinoma, Renal Cell; Diagnosis, Differential; Drug Eruptions; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Middle Aged; Nevus, Pigmented; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Skin; Skin Neoplasms; Sorafenib	2008
Localized palmar-plantar epidermal hyperplasia associated with use of sorafenib. Clinical drug investigation, 2008, Volume: 28, Issue:12 Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Eruptions; Erythema; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib	2008
Generalised erythematous skin eruptions induced by sorafenib: cutaneous toxicity and treatment outcome. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2008, Volume: 10, Issue:12 Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dermatitis, Exfoliative; Drug Eruptions; Female; Humans; Kidney Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Skin; Sorafenib; Treatment Outcome	2008
Cutaneous drug eruptions induced by sorafenib: a case series. Journal of drugs in dermatology : JDD, 2008, Volume: 7, Issue:9 Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Erythema; Female; Humans; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib	2008
Perforating folliculitis, angioedema, hand-foot syndrome--multiple cutaneous side effects in a patient treated with sorafenib. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2009, Volume: 7, Issue:5 Topics: Aged; Angioedema; Antineoplastic Agents; Benzenesulfonates; Diagnosis, Differential; Drug Eruptions; Folliculitis; Foot Dermatoses; Hand Dermatoses; Humans; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Syndrome	2009
Tyrosine kinase inhibitors in advanced renal cell carcinoma: the evolving treatment paradigm. Clinical genitourinary cancer, 2009, Volume: 7, Issue:1 Topics: Benzenesulfonates; Carcinoma, Renal Cell; Drug Eruptions; Foot Diseases; Hand Dermatoses; Humans; Indoles; Kidney Neoplasms; Niacinamide; Paresthesia; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib	2009
Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clinical genitourinary cancer, 2009, Volume: 7, Issue:1 Topics: Aged; Benzenesulfonates; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Drug Eruptions; Female; Humans; Inflammation; Keratoacanthoma; Keratosis, Actinic; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Skin Neoplasms; Sorafenib	2009
[Hand-foot syndrome and sorafenib]. Bulletin du cancer, 2009, Volume: 96, Issue:2 Topics: Benzenesulfonates; Dermatology; Drug Eruptions; Foot Dermatoses; Hand Dermatoses; Humans; Kidney Neoplasms; Liver Neoplasms; Medical Oncology; Niacinamide; Pharmacy; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Skin; Sorafenib; Syndrome	2009
Erythema multiforme induced by sorafenib. Clinical and experimental dermatology, 2009, Volume: 34, Issue:7 Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Eruptions; Erythema Multiforme; Female; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib	2009
Localized dyskeratotic plaque with milia associated with sorafenib. Journal of drugs in dermatology : JDD, 2009, Volume: 8, Issue:6 Topics: Acantholysis; Benzenesulfonates; Carcinoma, Hepatocellular; Diabetes Mellitus; Drug Eruptions; Hepatitis B; Humans; Keratosis; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib	2009
Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. The British journal of dermatology, 2009, Volume: 161, Issue:5 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Drug Eruptions; Female; Foot Dermatoses; Gastrointestinal Stromal Tumors; Hand Dermatoses; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Skin Diseases; Sorafenib; Stomatitis; Sunitinib; Young Adult	2009
Array of cutaneous adverse effects associated with sorafenib. Journal of the American Academy of Dermatology, 2009, Volume: 61, Issue:2 Topics: Benzenesulfonates; Biopsy, Needle; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; Female; Humans; Immunohistochemistry; Incidence; Male; Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Prospective Studies; Pyridines; Risk Assessment; Skin Diseases; Sorafenib	2009
Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma. American journal of clinical oncology, 2010, Volume: 33, Issue:3 Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Drug Administration Schedule; Drug Eruptions; Female; Humans; Hypertension; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib	2010
[Palmoplantar cutaneous reaction to sorafenib]. Actas dermo-sifiliograficas, 2009, Volume: 100, Issue:8 Topics: Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Foot Dermatoses; Hand Dermatoses; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Skin Diseases, Vesiculobullous; Sorafenib	2009
Lack of association between excretion of sorafenib in sweat and hand-foot skin reaction. Pharmacotherapy, 2010, Volume: 30, Issue:1 Topics: Antineoplastic Agents; Benzenesulfonates; Chromatography, High Pressure Liquid; Drug Eruptions; Female; Foot Dermatoses; Hand Dermatoses; Humans; Iontophoresis; Limit of Detection; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pilocarpine; Pilot Projects; Protein Kinase Inhibitors; Pyridines; Severity of Illness Index; Sorafenib; Sweat; Tandem Mass Spectrometry	2010
Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. The oncologist, 2010, Volume: 15, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Drug Eruptions; Exanthema; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Survival Analysis	2010
Sorafenib-induced psoriasiform eruption in a patient with metastatic thyroid carcinoma. Journal of drugs in dermatology : JDD, 2010, Volume: 9, Issue:2 Topics: Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Humans; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Psoriasis; Pyridines; Sorafenib; Thyroid Neoplasms	2010
Sorafenib for recurrent hepatocellular carcinoma after liver transplantation. Japanese journal of clinical oncology, 2010, Volume: 40, Issue:8 Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Drug Eruptions; Female; Hematologic Diseases; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Retrospective Studies; Sorafenib; Survival Rate	2010
Non-pigmenting fixed drug eruption induced by sorafenib. Acta dermato-venereologica, 2010, Volume: 90, Issue:3 Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Biopsy; Carcinoma, Renal Cell; Drug Eruptions; Erythema; Humans; Kidney Neoplasms; Male; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Skin; Sorafenib	2010
Sorafenib-associated psoriasiform skin changes. Cutis, 2010, Volume: 85, Issue:6 Topics: Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Hand; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Psoriasis; Pyridines; Sorafenib	2010
Managing patients receiving sorafenib for advanced hepatocellular carcinoma: a case study. International journal of palliative nursing, 2010, Volume: 16, Issue:5 Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Continuity of Patient Care; Diarrhea; Drug Eruptions; Drug Monitoring; Female; Humans; Hypertension; Liver Neoplasms; Niacinamide; Nurse's Role; Oncology Nursing; Patient Care Team; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Safety; Sorafenib	2010
[Recommendations for the management of Sorafenib in patients with hepatocellular carcinoma]. Gastroenterologia y hepatologia, 2010, Volume: 33, Issue:10 Topics: Administration, Oral; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cardiovascular Diseases; Clinical Trials as Topic; Drug Eruptions; Drug Interactions; Drug Monitoring; Gastrointestinal Diseases; Humans; Liver Cirrhosis; Liver Neoplasms; Molecular Targeted Therapy; Neoplasm Proteins; Niacinamide; Patient Selection; Phenylurea Compounds; Practice Guidelines as Topic; Protein Kinase Inhibitors; Pyridines; Radiography; raf Kinases; Sorafenib; Spain	2010
Spiny follicular hyperkeratosis eruption: a new cutaneous adverse effect of sorafenib. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Nov-01, Volume: 28, Issue:31 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Benzenesulfonates; Drug Eruptions; Female; Folliculitis; Humans; Keratosis; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinases; Pyridines; Skin; Sorafenib	2010
Invasive squamous cell carcinoma and sorafenib in a black patient. Archives of dermatology, 2011, Volume: 147, Issue:1 Topics: Antineoplastic Agents; Benzenesulfonates; Black People; Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Drug Eruptions; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Skin Neoplasms; Sorafenib	2011
Sorafenib-induced acute localized exanthematous pustulosis in a patient with hepatocellular carcinoma. The British journal of dermatology, 2011, Volume: 165, Issue:2 Topics: Acute Generalized Exanthematous Pustulosis; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Eruptions; Female; Humans; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib	2011
Severe sorafenib-induced hand-foot skin reaction. Dermatology online journal, 2011, May-15, Volume: 17, Issue:5 Topics: Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Carcinoma, Hepatocellular; Clobetasol; Disease Progression; Drug Eruptions; Fatal Outcome; Foot Dermatoses; Hand Dermatoses; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib	2011
Sorafenib-induced eruption resembling pityriasis rubra pilaris. Journal of the American Academy of Dermatology, 2011, Volume: 65, Issue:2 Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Biopsy, Needle; Diagnosis, Differential; Drug Eruptions; Humans; Immunohistochemistry; Male; Niacinamide; Phenylurea Compounds; Pityriasis Rubra Pilaris; Pyridines; Risk Assessment; Severity of Illness Index; Sorafenib	2011
[Adverse effects of new oncologic therapies]. Praxis, 2011, Jul-27, Volume: 100, Issue:15 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Cetuximab; Colonic Neoplasms; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Facial Dermatoses; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib; Trastuzumab	2011
Interstitial granulomatous drug reaction to sorafenib. Archives of dermatology, 2011, Volume: 147, Issue:9 Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Foot Dermatoses; Granuloma; Hand Dermatoses; Humans; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib	2011
Chloracne-like drug eruption associated with sorafenib. Journal of drugs in dermatology : JDD, 2011, Volume: 10, Issue:11 Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chloracne; Drug Eruptions; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib	2011
Erythema multiforme-like drug reaction to sorafenib. Journal of drugs in dermatology : JDD, 2011, Volume: 10, Issue:12 Topics: Adult; Benzenesulfonates; Diagnosis, Differential; Drug Eruptions; Erythema Multiforme; Female; Hand Dermatoses; Humans; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib	2011
[Relationship between sorafenib-associated hand-food skin reaction and efficacy in treatment of advanced hepatocellular carcinoma]. Zhonghua yi xue za zhi, 2012, Apr-03, Volume: 92, Issue:13 Topics: Adult; Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Drug Eruptions; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Retrospective Studies; Sorafenib	2012
Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor. Clinical and experimental dermatology, 2006, Volume: 31, Issue:6 Topics: Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Humans; Keratosis; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Photosensitivity Disorders; Protein Kinase Inhibitors; Pyridines; Sorafenib	2006
Hand-foot and stump syndrome to sorafenib. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Jan-20, Volume: 25, Issue:3 Topics: Amputation Stumps; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Eruptions; Foot; Hand; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Syndrome	2007
Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib. The oncologist, 2007, Volume: 12, Issue:10 Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Eruptions; Erythema; Humans; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Skin Diseases; Sorafenib	2007
Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. The British journal of dermatology, 2008, Volume: 158, Issue:3 Topics: Aged; Aged, 80 and over; Benzenesulfonates; Blister; Carcinoma, Renal Cell; Drug Eruptions; Female; Foot Dermatoses; Hand Dermatoses; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome	2008